Our Take
Shorter approval windows are real but the speed gain is modest—25 days off 140 is not a manufacturing unlock, and India still lags peer-nation timelines that already operate sub-90-day cycles.
Why it matters
India manufactures medical devices for domestic and export markets. Faster licensing reduces time-to-market for domestic players and can tighten supply-chain timing for hospitals and distributors. The move also signals India's bid to compete with regulatory efficiency in developed markets.
Do this week
Device manufacturers: submit pending Class B and C applications now before final rules ship, since current statutory timelines still apply until the amended rules take effect.
India's Health Ministry Cuts Medical Device License Timelines
The Union health ministry released a draft notification (published in the official gazette on June 29, 2026) proposing amendments to the Medical Devices Rules, 2017. The changes reduce processing timelines for manufacturing licenses across four risk-based device categories.
Class B medical devices—low to moderate risk items such as blood pressure monitors, hypodermic needles, and pulse oximeters—will see license approval timelines cut from 140 days to 115 days. Class C and D devices, which include high-risk products like cardiac stents and orthopedic implants, will shift from 105 days to 90 days (per the official ministry statement).
The draft also layers in clearer intermediate timelines for each stage of licensing: application scrutiny, third-party audits by notified bodies, compliance verification, and license issuance. The health ministry framed this as a transparency and predictability improvement.
The notification is now open for public comment via the Central Drugs Standard Control Organisation (CDSCO) website. No timeline for final rule adoption was announced.
Modest Speed, Real Market Friction
A 25-day reduction in approval time is not trivial for manufacturers planning product launches, but it does not erase India's regulatory lag. Many peer markets—Singapore, South Korea, and the EU—already operate sub-90-day approval windows for comparable device classes. India's revised 90-day floor for high-risk devices still sits at the slower end of the global range.
The practical effect depends on execution. Clearer timelines help, but if notified bodies lack capacity or audit backlogs persist, statutory timelines alone won't move the needle. The draft does not address auditor staffing or infrastructure.
For domestic manufacturers, faster approvals reduce working-capital drag and time-to-revenue. For hospitals and distributors, shorter lead times on device availability matter most during supply shortages or emergency procurement. For India's export ambitions in medical devices—a sector the government has prioritized—regulatory speed is a competitive lever against Bangladesh and Vietnam.
What to Do This Week
Manufacturers: Review your current pending applications now. If Class B or C licenses are in audit or verification stages, audit the current statutory timeline and expected completion date. The new rules will not retroactively apply to applications filed before the amendment takes effect, so expect current timelines to hold. File any new applications only after the final rule is published; submitting now buys nothing if the rules are finalized in 2-3 months.
Hospital procurement teams: Flag devices currently on extended lead times. Once the new rules settle, request updated timelines from suppliers—domestic manufacturers may accelerate product launches by 2-3 weeks, which can matter for inventory planning.
Regulatory consultants: Start drafting comments for the public-comment period. Highlight audit capacity bottlenecks if you see them in client data; the ministry is unlikely to reduce timelines further if notified bodies cannot absorb the volume.